|
RAPGEF6 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.35889086042107E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.45209999580231E-09 |
| Normal-vs-Stage2 |
2.50199999995981E-06 |
| Normal-vs-Stage3 |
4.38180003392574E-09 |
| Normal-vs-Stage4 |
5.59310042724803E-10 |
| Stage1-vs-Stage2 |
5.261000E-01 |
| Stage1-vs-Stage3 |
7.333700E-02 |
| Stage1-vs-Stage4 |
7.017100E-03 |
| Stage2-vs-Stage3 |
5.300800E-01 |
| Stage2-vs-Stage4 |
1.883840E-01 |
| Stage3-vs-Stage4 |
3.573600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.30904226031726E-12 |
| Normal-vs-AfricanAmerican |
1.495180E-03 |
| Normal-vs-Asian |
2.44339999999621E-06 |
| Caucasian-vs-AfricanAmerican |
4.006600E-01 |
| Caucasian-vs-Asian |
9.858600E-01 |
| AfricanAmerican-vs-Asian |
4.637800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.30770000278591E-09 |
| Normal-vs-Female |
3.58030272096244E-11 |
| Male-vs-Female |
1.340570E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.31589999954984E-07 |
| Normal-vs-Age(41-60Yrs) |
1.01689767717517E-11 |
| Normal-vs-Age(61-80Yrs) |
2.01170002878115E-09 |
| Normal-vs-Age(81-100Yrs) |
2.876100E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.517700E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.348490E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.820000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.752600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.112400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.874000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.427500E-02 |
| Classical-VS-Follicular |
2.142400E-02 |
| Classical-VS-Other |
8.811900E-02 |
| Classical-VS-Normal |
6.50910000010718E-07 |
| Tall-VS-Follicular |
7.264400E-01 |
| Tall-VS-Other |
3.838600E-01 |
| Tall-VS-Normal |
4.49649999456625E-08 |
| Follicular-VS-Other |
3.339400E-01 |
| Follicular-VS-Normal |
7.12059999852244E-09 |
| Other-VS-Normal |
8.220600E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.833000500857E-11 |
| Normal-vs-N1 |
2.04469999820489E-08 |
| N0-vs-N1 |
4.325000E-01 |
|
|
